BIOGEN - TO CONTINUE TO URGE CMS TO ALIGN MEDICARE COVERAGE FOR CLASS OF AMYLOID-DIRECTED THERAPIES WITH POPULATIONS STUDIED IN RESPECTIVE CLINICAL TRIALS, FOR APPROPRIATE USE